Published in Lung on January 01, 1985
Langerhans cell histiocytosis--clinical and epidemiological aspects. Br J Cancer Suppl (1994) 1.38
Smoking-related interstitial lung diseases: radiologic-pathologic correlation. Eur Radiol (2006) 0.82
An unusual radiological presentation of pulmonary Langerhans' cell histiocytosis. BMJ Case Rep (2012) 0.75
Eosinophilic granuloma of the lung presenting as a solitary pulmonary nodule. Thorax (1990) 0.75
Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med (1976) 4.85
Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis (1990) 4.75
Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med (1974) 4.31
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Bronchoalveolar lavage. Am Rev Respir Dis (1987) 2.87
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization. J Clin Invest (1980) 2.50
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Pulmonary host defenses. I. Analysis of protein and lipids in bronchial secretions and antibody responses after vaccination with pseudomonas aeruginosa. J Immunol (1973) 2.25
Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest (1977) 2.24
Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. N Engl J Med (1979) 2.13
Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest (1975) 2.04
Pulmonary host defenses. II. Interaction of respiratory antibodies with Pseudomonas aeruginosa and alveolar macrophages. J Immunol (1973) 1.92
Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest (1984) 1.86
Pseudomonas pneumonia. A retrospective study of 36 cases. Am J Med (1973) 1.83
Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. Am J Med (1975) 1.81
Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J Immunol (1974) 1.73
Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. J Clin Invest (1981) 1.57
Pneumonia in the intensive care unit setting. J Intensive Care Med (1993) 1.48
Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis (1983) 1.47
Secretory component deficiency. A disorder of the IgA immune system. N Engl J Med (1976) 1.41
Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis (1987) 1.34
Gallium-67 citrate scanning in the staging of idiopathic pulmonary fibrosis: Correlation and physiologic and morphologic features and bronchoalveolar lavage. Am Rev Respir Dis (1978) 1.27
IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis (1985) 1.25
Concentrations of gentamicin and carbenicillin in bronchial secretions. J Infect Dis (1973) 1.23
Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis (1975) 1.22
Immunity to experimental cholera. II. Secretory and humoral antitoxin response to local and systemic toxoid administration. J Infect Dis (1975) 1.20
Mucoid Pseudomonas aeruginosa. A sign of cystic fibrosis in young adults with chronic pulmonary disease? JAMA (1976) 1.19
Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects. Quantitation and comparison with immunoglobulins A and E. Am Rev Respir Dis (1985) 1.18
Characterization of lymphocytes in bronchial lavage fluid from monkeys. J Immunol (1976) 1.14
Use of Pseudomonas aeruginosa lipopolysaccharide immunoadsorbents to prepare high potency, mono-specific antibodies. J Immunol Methods (1980) 1.12
Structural units of canine serum and secretory immunoglobulin A. Biochemistry (1971) 1.11
Respiratory infection complicating long-term tracheostomy. The implication of persistent gram-negative tracheobronchial colonization. Chest (1984) 1.10
Development of cellular and humoral immunity in the respiratory tract of rabbits to Pseudomonas lipopolysaccharide. J Clin Invest (1974) 1.08
Pulmonary host defenses in rabbits after immunization with Pseudomonas antigens: the interaction of bacteria, antibodies, macrophages, and lymphocytes. J Infect Dis (1974) 1.07
Free secretory component and other proteins in human lung lavage. Am Rev Respir Dis (1980) 1.06
Bronchoalveolar lavage. The report of an international conference. Chest (1986) 1.06
Vi antigen from Salmonella typhosa and immunity against typhoid fever. 11. Safety and antigenicity in humans. Infect Immun (1975) 1.02
Kinetic analysis of respiratory tract proteins recovered during a sequential lavage protocol. Am Rev Respir Dis (1982) 1.01
Receptors for human IgG subclasses on human alveolar macrophages. Am Rev Respir Dis (1984) 1.01
Bronchoalveolar lavage cells and proteins in patients with the acquired immunodeficiency syndrome. An immunologic analysis. Ann Intern Med (1985) 1.00
Hypersensitivity pneumonitis. Clin Chest Med (1982) 0.99
Air-space immunoglobulin production and levels in bronchoalveolar lavage fluid of normal subjects and patients with sarcoidosis. Am Rev Respir Dis (1983) 0.98
Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide. Am Rev Respir Dis (1986) 0.97
Granulocyte transfusion therapy of experimental Pseudomonas pneumonia. J Clin Invest (1974) 0.97
The importance of lymphocytes in pulmonary health and disease. Lung (1978) 0.96
Lung inflammation: role of endogenous chemotactic factors in attracting polymorphonuclear granulocytes. Am Rev Respir Dis (1983) 0.95
Experimental Pseudomonas pneumonia in leukopenic dogs: comparison of therapy with antibiotics and granulocyte transfusions. Blood (1976) 0.92
Alterations in the antibacterial properties of rabbit pulmonary macrophages exposed to wood smoke. Am Rev Respir Dis (1984) 0.92
Modes of tracheal gas insufflation. Comparison of continuous and phase-specific gas injection in normal dogs. Am Rev Respir Dis (1993) 0.91
Immunologic responses in the gastrointestinal tract of the guinea pig. I. Characterization of Peyer's patch cells. J Immunol (1973) 0.90
Quantitation of carcinoembryonic antigen in the lung lining fluid of normal smokers and nonsmokers. Am Rev Respir Dis (1981) 0.90
Altered immune status in the elderly. Semin Respir Infect (1990) 0.90
Nutritional status and bacterial binding in the lower respiratory tract in patients with chronic tracheostomy. Ann Intern Med (1984) 0.89
Lung host defenses: a status report. Chest (1979) 0.89
Respiratory tract fluids: analysis of content and contemporary use in understanding lung diseases. Dis Mon (1984) 0.88
ELISA analysis of BACTEC bottles for the earlier diagnosis of tuberculosis. Am Rev Respir Dis (1989) 0.88
Pharmacokinetics of gentamicin sulfate in bronchial secretions. J Infect Dis (1975) 0.88
Influence of sputum IgA and elastase on tracheal cell bacterial adherence. Am Rev Respir Dis (1986) 0.88
Safety of bronchoalveolar lavage in the critically ill, mechanically ventilated patient. Crit Care Med (1991) 0.88
Peyer's patch lymphocytes: demonstration of the integrity of afferent and efferent T-cell functions in the guinea pig and rat. J Immunol (1974) 0.87
Changes in the composition of canine respiratory cells obtained by bronchial lavage following irradiation or drug immunosuppression. Proc Soc Exp Biol Med (1976) 0.87
Chediak-Higashi syndrome: reversal of increased susceptibility to infection by bone marrow transplantation. Blood (1976) 0.87
Histamine levels in bronchoalveolar lavage from patients with asthma, sarcoidosis, and idiopathic pulmonary fibrosis. J Allergy Clin Immunol (1987) 0.86
Lung inflammation: normal host defense or a complication of some diseases? Annu Rev Med (1987) 0.86
A smoking cessation telephone resource: feasibility and preliminary evidence on the effect on health care provider adherence to smoking cessation guidelines. Tob Control (2002) 0.86
Human alveolar macrophage subpopulations isolated on discontinuous albumin gradients: functional data in normals and sarcoid patients. Eur J Respir Dis (1986) 0.86
Kinetics of immunoglobulin transport into canine bronchial secretions. Proc Soc Exp Biol Med (1976) 0.86
NHLBI workshop summary. Research needs and opportunities related to respiratory health of women. Am Rev Respir Dis (1992) 0.86
Tracheal gas insufflation augments CO2 clearance during mechanical ventilation. Am Rev Respir Dis (1993) 0.86
Experimental pneumonia due to Pseudomonas aeruginosa in leukopenic dogs: prolongation of survival by combined treatment with passive antibody to Pseudomonas and granulocyte transfusions. J Infect Dis (1977) 0.85
Canine immunoglobulins. 3. Distribution of immunoglobulins in colostrum and isolation of secretory IgA 7S gamma 1. J Immunol (1970) 0.85
Lung immunology and its contribution to the immunopathogenesis of certain respiratory diseases. J Allergy Clin Immunol (1986) 0.85
Demonstration of a free elastolytic metalloenzyme in human lung lavage fluid and its relationship to alpha 1-antiprotease. Am Rev Respir Dis (1984) 0.85
Bacterial adherence to respiratory tract cells. Relationships between in vivo and in vitro pH and bacterial attachment. Am Rev Respir Dis (1986) 0.84
Tobramycin in bronchial secretions. Antimicrob Agents Chemother (1973) 0.84
Structural composition of canine secretory component and immunoglobulin A. Biochemistry (1975) 0.83
5-fluorocytosine and amphotericin B in bronchial secretions. Antimicrob Agents Chemother (1974) 0.83
Pulmonary consequences of congenital and acquired primary immunodeficiency states. Clin Chest Med (1989) 0.83
Phagocytic defense in the lung. Antibiot Chemother (1971) (1985) 0.83
Lung mechanics and gas exchange during pressure-control ventilation in dogs. Augmentation of CO2 elimination by an intratracheal catheter. Am Rev Respir Dis (1992) 0.83
Respiratory infections may reflect deficiencies in host defense mechanisms. Dis Mon (1985) 0.82
Bronchial lavage in inflammatory lung disease. Clin Chest Med (1983) 0.82
Cellular immunity in Peyer's patches of rats infected with Trichinella spiralis. Infect Immun (1976) 0.82
Changing spectrum of pneumonia--news media creation or clinical reality? Am J Med (1983) 0.82
Airway changes in young smokers that may antedate chronic obstructive lung disease. Med Clin North Am (1981) 0.82
Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism. Possible mechanisms of pulmonary pharmacotoxicity. Am Rev Respir Dis (1986) 0.81
Immunologic concepts relating to the pathogenesis of diffuse interstitial lung diseases (emphasizing granulomatous forms and idiopathic pulmonary fibrosis). Trans Am Clin Climatol Assoc (1980) 0.81
Pseudomonas respiratory infection in cystic fibrosis: a possible defect in opsonic IgG antibody? Bull Eur Physiopathol Respir (1983) 0.81
Human alveolar macrophage subpopulations isolated on discontinuous albumin gradients. Cytological data in normals and sarcoid patients. Eur J Respir Dis (1986) 0.80
Immunoglobulin A in secretions from the lower human respiratory tract. Adv Exp Med Biol (1978) 0.80
Canine immunoglobulins. IV. Copro-immunoglobulins. J Immunol (1970) 0.80
Tracheal gas insufflation during pressure-control ventilation. Effect of catheter position, diameter, and flow rate. Am Rev Respir Dis (1992) 0.80
Immunologic lung disease (part 2). Chest (1982) 0.79
Serum immunoglobulin levels in grey collies. Proc Soc Exp Biol Med (1971) 0.79
Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients. Pediatr Infect Dis (1983) 0.79
Reaginic antibody in the lung lining fluid. Analysis of nomal human bronchoalveolar lavage fluid IgE and comparison to immunoglobulins G and A. J Lab Clin Med (1980) 0.78
Human alveolar macrophages release a factor that inhibits phagocyte function. Am J Respir Cell Mol Biol (1989) 0.78
Neutrophil chemotactic activity produced by normal and activated human bronchoalveolar lavage cells. J Lab Clin Med (1987) 0.78